Age and tumour presentations differ between HPV type 16 positive and other high‐risk HPV type‐positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000–2022
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Anders Näsman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Papillomavirus Infections, Oropharyngeal Neoplasms, Human papillomavirus 16, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Stockholm Cancer Foundation, Swedish Cancer Foundation, Karolinska Institutet.
Abstract (Originalsprache)
The incidence of human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) has increased the past decades. Initial reports disclosed that HPV type 16 (HPV16) was predominant and that patients with HPV+ OPSCC were generally younger and had a better prognosis than those with HPV negative (HPV−) OPSCC. However, recent reports suggest that age differences between patients with HPV+ and HPV−OPSCC are less pronounced and that other high‐risk HPV types (HR‐HPV) are becoming more common. Here, we therefore investigated whether there were age differences between patients with HPV16‐positive and other HR‐HPV type positive OPSCC. During 2000–2022, in the Stockholm–Gotland‐Region, Sweden, 1681 patients with OPSCC tested for the presence of common mucosal HPV types were included. Among these, 1180 cases had a HR‐HPV type infection, with 1032 identified as HPV16 and 148 as other HR‐HPV types; one with a low‐risk HPV type infection; and 500 classified as HPV−. Patients with HPV+ OPSCC were significantly younger than those with HPV− OPSCC (mean 63 vs. 66.5, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Pathology, Karolinska University Hospital, Stockholm, Sweden.
- Medical Unit Head, Neck, Lung, and Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
- Division of Ear Nose and Throat Diseases, Department of Clinical Sciences Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Medical Unit Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Surgical Sciences, Section of Otolaryngology and Head and Neck Surgery, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Anders Näsman, Evelina Jörtsö, Mark Zupancic, Rusana Bark, Tina Dalianis
Förderung
- The Stockholm Cancer Foundation
- Swedish Cancer Foundation
- Karolinska Institutet
- Insamlingsstiftelsen Cancer- och Allergifonden
- Stockholm City Council
- Kommunfullmäktige, Stockholms Stad
Zitieren
APA
Näsman, A., Birgersson, M., Näsman, T., Jörtsö, E., Zupancic, M., Bark, R., Marklund, L., & Dalianis, T. (2025). Age and tumour presentations differ between HPV type 16 positive and other high‐risk HPV type‐positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000–2022. International Journal of Cancer. https://doi.org/10.1002/ijc.70087
Vancouver
Näsman A, Birgersson M, Näsman T, Jörtsö E, Zupancic M, Bark R, et al. Age and tumour presentations differ between HPV type 16 positive and other high‐risk HPV type‐positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000–2022. International Journal of Cancer. 2025. doi:10.1002/ijc.70087
BibTeX
@article{Nsman2025,
author = {Näsman, Anders and Birgersson, Madeleine and Näsman, Tobias and Jörtsö, Evelina and Zupancic, Mark and Bark, Rusana and Marklund, Linda and Dalianis, Tina},
title = {Age and tumour presentations differ between HPV type 16 positive and other high‐risk HPV type‐positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000–2022},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70087}
}
EUVIMED